Home › Funds › BRAIDWELL LP › KYMR
BRAIDWELL LP position in KYMR
KYMERA THERAPEUTICS INC · Health Care
BRAIDWELL LP reported holding 378,163 shares of KYMR (KYMERA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$43.4M, representing 1.71% of its reported portfolio and ranking #18 among its reported holdings. BRAIDWELL LP has disclosed KYMR holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BRAIDWELL LP's KYMR position evolved
BRAIDWELL LP first disclosed a stake in KYMR in Q3 2025 at 276,692 shares (US$15.7M). The position peaked in Q2 2026 at 378,163 shares, worth US$43.4M. Across 4 filings, BRAIDWELL LP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 378,163 shares valued at US$43.4M — an increase of 40,604 shares quarter over quarter.. Notable position changes include a 64% increase in Q4 2025 (shares rose 7% over the following quarter), a 26% trim in Q1 2026 (shares rose 38% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 276.69K | $15.66M | New |
| Q4 2025 | 454.26K | $35.35M | Add |
| Q1 2026 | 337.56K | $28.12M | Reduce |
| Q2 2026 | 378.16K | $43.36M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KYMR and 13F data
KYMR (KYMERA THERAPEUTICS INC) is a Health Care company. 57 other funds we track also report a position in KYMR — the largest reported positions include BAKER BROS. ADVISORS LP (US$992.7M), Avoro Capital Advisors LLC (US$857.1M), T. Rowe Price Investment Management, Inc. (US$717.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KYMR
- BAKER BROS. ADVISORS LP 8.66M sh · $992.73M · Q2 2026
- Avoro Capital Advisors LLC 7.47M sh · $857.13M · Q2 2026
- T. Rowe Price Investment Management, Inc. 6.26M sh · $717.52M · Q2 2026
- BVF INC/IL 3.87M sh · $444.01M · Q2 2026
- Siren, L.L.C. 2.94M sh · $336.65M · Q2 2026
- Atlas Venture Life Science Advisors, LLC 2.85M sh · $326.53M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 919.23K sh · $105.41M · Q2 2026
- Merck & Co., Inc. 772.16K sh · $88.54M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 740.87K sh · $84.96M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 504.21K sh · $57.81M · Q2 2026
- Rock Springs Capital Management LP 453.16K sh · $51.96M · Q2 2026
- Boxer Capital Management, LLC 429.10K sh · $49.20M · Q2 2026
More on BRAIDWELL LP
FAQ
How long has BRAIDWELL LP held KYMR?
BRAIDWELL LP has disclosed KYMR holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is BRAIDWELL LP's current position in KYMR?
As of Q2 2026, BRAIDWELL LP holds 378.16K shares of KYMR (KYMERA THERAPEUTICS INC), valued at $43.36M, representing 1.71% of its reported portfolio and ranking #18.
Has BRAIDWELL LP been buying or selling KYMR?
In the latest 13F filing (Q2 2026), BRAIDWELL LP increased its position in KYMR. The position peaked in Q2 2026 at 378.16K shares.
Which other funds hold KYMR?
Other major institutional holders of KYMR include BAKER BROS. ADVISORS LP, Avoro Capital Advisors LLC, T. Rowe Price Investment Management, Inc., among 57 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.